{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"66.2","upperLimit":"74.3","value":"70.2"},{"groupId":"OG001","lowerLimit":"56.7","upperLimit":"68.9","value":"62.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"484"},{"groupId":"OG001","value":"242"}],"units":"Participants"}],"description":"CBR was defined as the percentage of participants with a best overall response of CR or PR or stable disease (SD) lasting 24 weeks or longer as defined in RECIST 1.1 as per investigator assessment.\n\nCR: Disappearance of all lesions with lymph nodes measuring \\< 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.\n\nSD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ribociclib was administered orally at a daily dose of 600mg for 21 consecutive days within a 28-day cycle. This treatment was combined with fulvestrant, which was administered via intramuscular injections of 500mg every 28 days starting on Day 1 of each cycle. Additionally, an extra dose of fulvestrant was given on Day 15 of Cycle 1.","id":"OG000","title":"Ribociclib + Fulvestrant"},{"description":"Placebo was administered orally for 21 consecutive days within a 28-day cycle. This treatment was combined with fulvestrant, which was administered via intramuscular injections of 500mg every 28 days starting on Day 1 of each cycle. Additionally, an extra dose of fulvestrant was given on Day 15 of Cycle 1.","id":"OG001","title":"Placebo + Fulvestrant"}],"paramType":"NUMBER","populationDescription":"FAS including all randomized participants.","reportingStatus":"POSTED","timeFrame":"Up to approximately 26 months","title":"Clinical Benefit Rate (CBR) Per Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}